Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks

Limited population approval pathway in 21st Century Cures law may not help Cempra overcome US agency's request for new 9,000-patient safety study of the macrolide antibiotic.

Bacterias 3D rendering

Cempra Inc.'s antibiotic Solithera (solithromycin) has landed a complete response letter from the US FDA for community acquired bacterial pneumonia (CABP), and even the recently enacted 21st Century Cures legislation's limited population approval pathway may not be enough to save it from a large, pre-approval safety study.

In declining to approve Solithera, FDA said the company had not adequately characterized the macrolide antibiotic's safety profile – specifically...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Complete Response Letters

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>